Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Naloxone Sponsor Steps In Pricing Hole Disputing FDA's Cost Estimates

Dec 21 2018

• By Derrick Gingery

Drug costs_1B_546120055_1200.jpg

Related Content

Opioids Could Become Bioterror Weapons, US Fears; BARDA Funds Countermeasures

Sep 25 2018

Naloxone Mandate In Opioid Labels Divides US FDA Panel, Even As It Wants Patient Conversations

Dec 19 2018

Cost Concerns May Hinder Naloxone Co-Prescribing Ideas

Dec 14 2018

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Aug 30 2016

Related Companies

Adapt Pharma Limited

Emergent BioSolutions, Inc.

Opiant Pharmaceuticals, Inc.

Additional Topics

United States Advisory Committees Regulation Pricing Debate FDA Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.